Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 2
2006 5
2007 2
2008 5
2009 3
2010 1
2011 1
2012 11
2013 7
2014 18
2015 13
2016 7
2017 17
2018 26
2019 34
2020 32
2021 37
2022 34
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li X, Zhao C, Chen X, Su C, Ren S, Zhou C. Qiao M, et al. Among authors: chen x. J Thorac Oncol. 2021 Aug;16(8):1267-1288. doi: 10.1016/j.jtho.2021.04.003. Epub 2021 Apr 26. J Thorac Oncol. 2021. PMID: 33915248 Free article. Review.
SEC61G assists EGFR-amplified glioblastoma to evade immune elimination.
Zeng K, Zeng Y, Zhan H, Zhan Z, Wang L, Xie Y, Tang Y, Li C, Chen Y, Li S, Liu M, Chen X, Liang L, Deng F, Song Y, Zhou A. Zeng K, et al. Among authors: chen x. Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2303400120. doi: 10.1073/pnas.2303400120. Epub 2023 Jul 31. Proc Natl Acad Sci U S A. 2023. PMID: 37523556 Free PMC article.
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge DR, Hirsch FR. Zhao S, et al. Among authors: chen x. Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12. Cancer Immunol Res. 2019. PMID: 30755403 Clinical Trial.
EGFR-mutant NSCLC: emerging novel drugs.
Ye L, Chen X, Zhou F. Ye L, et al. Among authors: chen x. Curr Opin Oncol. 2021 Jan;33(1):87-94. doi: 10.1097/CCO.0000000000000701. Curr Opin Oncol. 2021. PMID: 33122578 Review.
274 results